All PLWH who are coinfected with HCV should be offered curative HCV treatment. Nonadherence to ART or a lack of HIV suppression should not affect candidacy for treatment of HCV.
Managing people living with both HIV and HCV and polypharmacy can be difficult. How do you analyze which HCV regimen to use and identify relevant drug interactions?
Treatment of HCV/HIV coinfection requires continued awareness of and attention to the complex drug–drug interactions that can occur, especially when using pharmacologically boosted ARVs and nonnucleoside reverse transcriptase inhibitors. Here’s my take on how to approach drug–drug interactions using patient cases.